Actively Recruiting
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Led by Yehui Tan · Updated on 2025-08-08
70
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
CONDITIONS
Official Title
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed acute myeloid leukemia patients confirmed by bone marrow morphology and immunophenotyping
- Complete MICM work-up (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics)
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Peripheral blood blast percentage on Day 6 of 1% or higher
- Renal function with creatinine clearance of 50 mL/min or greater
- Liver function with AST and ALT at most 2.5 times the upper limit of normal and total bilirubin at most 1.5 times the upper limit of normal (unless due to leukemia infiltration)
- Suitable for DA/IA chemotherapy as determined by the investigator
- Signed informed consent form
You will not qualify if you...
- Diagnosis of acute promyelocytic leukemia (APL)
- Mixed phenotype acute leukemia (MPAL)
- Known central nervous system involvement by AML
- Presence of extramedullary disease
- Significant liver or kidney dysfunction beyond inclusion limits
- Severe heart disease such as congestive heart failure or myocardial infarction
- Active malignancy in other organs (except cured cancers)
- Active tuberculosis or HIV infection
- Other hematological disorders
- Pregnancy or breastfeeding
- Unable to understand or follow study protocol
- Allergy to study drugs
- Unable to take oral medication or malabsorption syndrome
- Uncontrolled systemic infection
- Prior venetoclax treatment or current participation in other investigational studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Hospital of Jilin University
Changchun, Jilin, China, 130000
Actively Recruiting
Research Team
Y
Yehui Tan
CONTACT
Y
Yuying Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here